What is the equity of Immunic this year?
Immunic has equity of 18.43 M USD this year.
Immunic Equity 2025
Immunic Equity
18.43 M USD
Ticker
IMUX
ISIN
US4525EP1011
WKN
A2PHD4
In 2025, Immunic's equity was 18.43 M USD, a -36.3% increase from the 28.93 M USD equity in the previous year.
Immunic Aktienanalyse
What does Immunic do?
Immunic Inc is a biotechnology company specialized in the development of therapeutics for chronic inflammatory and autoimmune diseases. The company was founded in 2016 as a spin-off of the Max Planck Institute for Infection Biology in Berlin and is based in New York City. Immunic Inc aims to develop innovative drugs that improve the quality of life for patients with chronic inflammatory and autoimmune diseases and positively influence the course of their conditions. The business activities of Immunic Inc include the identification of new active substances, drug development, clinical studies, and drug approval by regulatory authorities. To accelerate drug development, the company collaborates with academic, regulatory, and pharmaceutical partners. Immunic Inc offers products in three different areas: autoimmune diseases, inflammatory diseases, and infectious diseases. Each area has various products and pipelines currently in development. In the field of autoimmune diseases, the main product of Immunic Inc is the substance IMU-838. This drug is a highly effective inhibitor of the DHODH enzyme family, which plays an essential role in mitochondrial DNA synthesis. IMU-838 is a very selective DHODH inhibitor with disease-specific effects against various autoimmune diseases. IMU-838 is one of the most promising candidates of Immunic Inc and is currently in phase II studies for the treatment of multiple sclerosis (MS), ulcerative colitis, and chronic inflammatory bowel diseases (CED). In the field of inflammatory diseases, Immunic Inc is developing a drug based on IMM-124E. This medication is an orally administered therapeutic agent that inhibits inflammatory reactions in the gastrointestinal tract. IMM-124E was initially developed as an antidote for arsenic poisoning but also shows promising results in the treatment of inflammatory diseases such as nonalcoholic steatohepatitis (NASH) and liver fibrosis. IMM-124E is currently in phase II studies for the treatment of these conditions. In the field of infectious diseases, Immunic Inc is developing various drugs that are effective against infections. This includes IMU-935, a selective HSV-1 inhibitor that has shown promise in the treatment of herpes simplex viruses (HSV) and other viral infections. IMU-935 also exhibits good activity against influenza viruses and cytomegaloviruses and is currently in phase I studies. Immunic Inc is an innovative biotechnology company developing innovative therapeutics for chronic inflammatory and autoimmune diseases. The company aims to improve the lives of patients with chronic conditions and positively influence the course of their diseases. By focusing on three different areas, the company is developing a broad portfolio of drugs in various stages of development and clinical testing. Immunic Inc has established strong partnerships with academic, regulatory, and pharmaceutical partners and will continue to operate successfully in the biotechnology field with promising products and pipelines in the coming years. Immunic ist eines der beliebtesten Unternehmen auf Eulerpool.com.Equity Details
Analyzing Immunic's Equity
Immunic's equity represents the ownership interest in the company, calculated as the difference between total assets and total liabilities. It reflects the residual claim by shareholders on the company’s assets after all debts have been paid. Understanding Immunic's equity is essential for assessing its financial health, stability, and value to shareholders.
Year-to-Year Comparison
Evaluating Immunic's equity over successive years offers insights into the company's growth, profitability, and capital structure. Increasing equity indicates an enhancement in net assets and financial health, while decreasing equity could point to rising debts or operational challenges.
Impact on Investments
Immunic's equity is a crucial element for investors, influencing the company's leverage, risk profile, and return on equity (ROE). Higher equity levels generally suggest lower risk and enhanced financial stability, making the company a potentially attractive investment opportunity.
Interpreting Equity Fluctuations
Fluctuations in Immunic’s equity can arise from various factors, including changes in net income, dividend payments, and issuance or buyback of shares. Investors analyze these shifts to gauge the company's financial performance, operational efficiency, and strategic financial management.
Frequently Asked Questions about Immunic stock
What was the equity of Immunic compared to the previous year?
The equity of Immunic has increased/decreased by -36.3% decreased compared to the previous year.
What impact does a high equity have on investors of Immunic?
A high equity is advantageous for investors of Immunic as it is an indicator of the company's financial stability and its ability to manage risks and challenges.
What impact does low equity have on investors of Immunic?
A low equity can be a risk for investors of Immunic, as it can put the company in a weaker financial position and impair its ability to manage risks and challenges.
How does an increase in equity of Immunic affect the company?
An increase in equity of Immunic can strengthen the company's financial position and improve its ability to make investments in the future.
How does a reduction in the equity of Immunic affect the company?
A reduction in equity of Immunic can affect the financial situation of the company and lead to a higher dependence on debt capital.
What are some factors that influence the equity of Immunic?
Some factors that can affect the equity of Immunic include profits, dividend payments, capital increases, and acquisitions.
Why is the equity of Immunic so important for investors?
The equity of Immunic is important for investors as it is an indicator of the financial strength of the company and can be an indication of how well the company is able to fulfill its financial obligations.
What strategic measures can Immunic take to change the equity?
To change equity, Immunic can take various measures such as increasing profits, conducting capital increases, reducing expenses, and acquiring companies. It is important for the company to perform a thorough review of its financial situation to determine the best strategic actions to modify its equity.
How much dividend does Immunic pay?
Over the past 12 months, Immunic paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Immunic is expected to pay a dividend of 0 USD.
What is the dividend yield of Immunic?
The current dividend yield of Immunic is .
When does Immunic pay dividends?
Immunic pays a quarterly dividend. This is distributed in the months of .
How secure is the dividend of Immunic?
Immunic paid dividends every year for the past 0 years.
What is the dividend of Immunic?
For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.
In which sector is Immunic located?
Immunic is assigned to the 'Health' sector.
Wann musste ich die Aktien von Immunic kaufen, um die vorherige Dividende zu erhalten?
To receive the latest dividend of Immunic from 6/22/2025 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 6/22/2025.
When did Immunic pay the last dividend?
The last dividend was paid out on 6/22/2025.
What was the dividend of Immunic in the year 2024?
In the year 2024, Immunic distributed 0 USD as dividends.
In which currency does Immunic pay out the dividend?
The dividends of Immunic are distributed in USD.
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.
Andere Kennzahlen von Immunic
Our stock analysis for Immunic Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Immunic Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.
